BACKGROUND: Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated with neoadjuvant chemotherapy (NAC) is uncertain. We assessed the effect of CIS found in pretreatment transurethral resection of bladder tumor (TURBT) biopsies on the pathologic and clinical outcomes. MATERIALS AND METHODS: Subjects with MIUC treated with NAC before cystectomy were identified. The pathologic complete response (pCR) rates stratified by TURBT CIS status were compared. The secondary analyses included tumor response, progression-free survival (PFS), overall survival (OS), and an exploratory post hoc analysis of patients with pathologic CIS only (pTisN0) at cystectomy. RESULTS: A total of 137 patients with MIUC were identified. TURBT CIS was noted in 30.7% of the patients. The absence of TURBT CIS was associated with a significantly increased pCR rate (23.2% vs. 9.5%; odds ratio, 4.08; 95% confidence interval, 1.19-13.98; P = .025). Stage pTisN0 disease was observed in 19.0% of the TURBT CIS patients. TURBT CIS status did not significantly affect the PFS or OS outcomes. Post hoc analysis of the pTisN0 patients revealed prolonged median PFS (104.5 vs. 139.9 months; P = .055) and OS (104.5 vs. 152.3 months; P = .091) outcomes similar to those for the pCR patients. CONCLUSION: The absence of CIS on pretreatment TURBT in patients with MIUC undergoing NAC was associated with increased pCR rates, with no observed differences in PFS or OS. Isolated CIS at cystectomy was frequently observed, with lengthy PFS and OS durations similar to those for pCR patients. Further studies aimed at understanding the biology and clinical effect of CIS in MIUC are warranted.
BACKGROUND:Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated with neoadjuvant chemotherapy (NAC) is uncertain. We assessed the effect of CIS found in pretreatment transurethral resection of bladder tumor (TURBT) biopsies on the pathologic and clinical outcomes. MATERIALS AND METHODS: Subjects with MIUC treated with NAC before cystectomy were identified. The pathologic complete response (pCR) rates stratified by TURBT CIS status were compared. The secondary analyses included tumor response, progression-free survival (PFS), overall survival (OS), and an exploratory post hoc analysis of patients with pathologic CIS only (pTisN0) at cystectomy. RESULTS: A total of 137 patients with MIUC were identified. TURBT CIS was noted in 30.7% of the patients. The absence of TURBT CIS was associated with a significantly increased pCR rate (23.2% vs. 9.5%; odds ratio, 4.08; 95% confidence interval, 1.19-13.98; P = .025). Stage pTisN0 disease was observed in 19.0% of the TURBT CIS patients. TURBT CIS status did not significantly affect the PFS or OS outcomes. Post hoc analysis of the pTisN0 patients revealed prolonged median PFS (104.5 vs. 139.9 months; P = .055) and OS (104.5 vs. 152.3 months; P = .091) outcomes similar to those for the pCR patients. CONCLUSION: The absence of CIS on pretreatment TURBT in patients with MIUC undergoing NAC was associated with increased pCR rates, with no observed differences in PFS or OS. Isolated CIS at cystectomy was frequently observed, with lengthy PFS and OS durations similar to those for pCR patients. Further studies aimed at understanding the biology and clinical effect of CIS in MIUC are warranted.
Authors: D L Lamm; B A Blumenstein; J D Crissman; J E Montie; J E Gottesman; B A Lowe; M F Sarosdy; R D Bohl; H B Grossman; T M Beck; J T Leimert; E D Crawford Journal: J Urol Date: 2000-04 Impact factor: 7.450
Authors: Daher C Chade; Shahrokh F Shariat; Guilherme Godoy; Caroline J Savage; Angel M Cronin; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni Journal: J Urol Date: 2010-07 Impact factor: 7.450
Authors: Philipp Nuhn; Patrick J Bastian; Giacomo Novara; Robert S Svatek; Pierre I Karakiewicz; Eila Skinner; Yves Fradet; Jonathan I Izawa; Wassim Kassouf; Francesco Montorsi; Stefan C Müller; Hans-Martin Fritsche; Guru Sonpavde; Derya Tilki; Hendrik Isbarn; Vincenzo Ficarra; Colin P Dinney; Shahrokh F Shariat Journal: Urol Int Date: 2011-06-09 Impact factor: 2.089
Authors: Marko Babjuk; Maximilian Burger; Richard Zigeuner; Shahrokh F Shariat; Bas W G van Rhijn; Eva Compérat; Richard J Sylvester; Eero Kaasinen; Andreas Böhle; Joan Palou Redorta; Morgan Rouprêt Journal: Eur Urol Date: 2013-06-12 Impact factor: 20.096
Authors: Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096
Authors: Elizabeth R Plimack; Jean H Hoffman-Censits; Rosalia Viterbo; Edouard J Trabulsi; Eric A Ross; Richard E Greenberg; David Y T Chen; Costas D Lallas; Yu-Ning Wong; Jianqing Lin; Alexander Kutikov; Efrat Dotan; Timothy A Brennan; Norma Palma; Essel Dulaimi; Reza Mehrazin; Stephen A Boorjian; William Kevin Kelly; Robert G Uzzo; Gary R Hudes Journal: J Clin Oncol Date: 2014-05-12 Impact factor: 44.544
Authors: N Vasdev; H Zargar; J P Noël; R Veeratterapillay; A S Fairey; L S Mertens; C P Dinney; M C Mir; L M Krabbe; M S Cookson; N E Jacobsen; N M Gandhi; J Griffin; J S Montgomery; E Y Yu; E Xylinas; N J Campain; W Kassouf; M A Dall'Era; J A Seah; C E Ercole; S Horenblas; S S Sridhar; J S McGrath; J Aning; S F Shariat; J L Wright; T M Morgan; T J Bivalacqua; S North; D A Barocas; Y Lotan; P Grivas; A J Stephenson; J B Shah; B W van Rhijn; S Daneshmand; P E Spiess; J M Holzbeierlein; A Thorpe; P C Black Journal: World J Urol Date: 2018-06-07 Impact factor: 4.226